Myoglobin Market - Regional Analysis
North America Market Insights
North America is leading the myoglobin market and will continue to capture the market share of 35.5% by 2035. The region is governed by high incidence rates of cardiovascular diseases, well-established healthcare facilities, and early adoption of diagnostic technologies. According to the NLM survey in February 2025, cardiovascular disease incidence in the area was 781 per 100,000 men versus 568 per 100,000 women in 2021. This increasing case is one of the major trends in incorporating myoglobin testing in overall cardiac panels in point-of-care settings to accelerate diagnosis.
The U.S. market is dominating the region and holds the highest share by 2035. The nation is driven by the high burden of cardiovascular disease and advanced diagnostic protocols. According to the CDC report in June 2024, 696,000 people in the U.S. died due to heart disease, which is the leading cause of death and creating a sustained demand for cardiac biomarkers. The American Heart Association emphasizes the critical importance of early detection, with myoglobin serving as an early indicator of myocardial infarction.
The Canada myoglobin market is defined by the universal healthcare system that standardizes the cardiac treatment protocols and ensures consistent uptake of biomarker testing. The country is fueled by the increased aging population and rising prevalence of cardiovascular risk factors. According to the report by Heart & Stroke in February 2025, the cost of heart disease and stroke exceeds USD 21.2 billion and USD 3.6 billion annually, highlighting the economic urgency for effective diagnostics. The rising heart diseases prioritize troponin to recognize the role of multi-marker strategies in specific clinical scenarios, which has led to the integration of myoglobin in the diagnostic centers.
Prevalence of Cardiovascular Disease
|
Metric |
U.S. |
Canada |
|
Cardiovascular Disease Deaths |
919,032 people died, ~1 in 3 deaths |
1 in 12 people |
|
Heart Attack Incidence |
About 805,000 people per year |
9 in 10 people |
Source: CDC October 2024, Heart and Stroke 2025, Government of Canada July 2022
APAC Market Insights
The Asia Pacific is the fastest growing region in the myoglobin market and is driven by the rising burden of cardiovascular disease and significant healthcare infrastructure improvements. The major drivers of the region include rising geriatric populations and increased hypertension and diabetes rates. As per the American College of Cardiology data in June 2021, the number of deaths due to cardiovascular disease is 10.8 million in Asia. Further, the strategic partnerships between international diagnostic giants and local manufacturers are expanding market access and affordability.
Japan's market is developed, with a high level of diagnostic infrastructure and care. The demand is led by the elderly population, with more than 36.23 million over the age of 65, according to World Economic Forum statistics in September 2023. Public expenditure via the universal health insurance system provides broad access to cardiac biomarker testing. A key initiative is the promotion of efficient diagnostic pathways to manage rising healthcare costs for age-related diseases, solidifying consistent market demand for established tests like myoglobin.
China dominates the myoglobin market in the region and is fueled by the massive healthcare investment by the government and the rising cardiovascular disease burden. The Healthy China 2030 program focuses on increasing life expectancy and enhancing the medical services, directly boosting the diagnostics market. According to the NLM study in June 2023, there are an estimated 330 million patients with cardiovascular disease. This rising case creates an immense market demand. Further, the market size is expanding due to the advancements in hospital capabilities. The government spending is aimed at early screening and prevention, which directly increases the cardiac biomarker tests.
Europe Market Insights
Europe is the second largest market and is driven by the advaced healthcare systems and strong regulatory frameworks. The growth of the market is primarily driven by the rising heart diseases and adoption of standardized clinincal guidelines for early diagnosis of acute myocardial infarction. Further, CVD cases in the region creates a consistent demand for cardiac biomarkers. A key trend is the integration of myoglobin into multi-marker cardiac panels alongside troponin and CK-MB, despite the rising dominance of high-sensitivity troponin testing.
The UK myoglobin market ranks third in Europe by size, with a robust public healthcare sector fueling standardized diagnostic practices. Demand is supported by a high and increasing burden of cardiovascular disease. The British Heart Foundation report in August 2025 illustrates that approximately 7.6 million individuals in the UK have heart or circulatory diseases, which makes them continually require cardiac biomarkers. In addition, use of myoglobin is integrated in pathology and emergency care services specifically for rapid chest pain assessment under National Institute for Health and Care Excellence guidance.
Germany is leading the market in Europe and is driven by its advanced healthcare infrastructure and high healthcare expenditure. The German Federal Statistical Office states that the circulatory disease is the leading cause of death in the country, accounting significant portion of hospitalizations. This high disease prevalence demands the market. The market is guided by robust standards set by the Federal Joint Committee (G-BA), which influences diagnostic reimbursement and protocols. Further, the high penetration of automated immunoassay systems in hospital laboratories, facilitates the efficient use of myoglobin within multi-marker cardiac panels for fast and accurate diagnosis.
